In COVID-19, tocilizumab reduces all-cause mortality at 28 d.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 34058104.
- Also identified by DOI 10.7326/ACPJ202106150-063.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Ghosn L, Chaimani A, Evrenoglou T, et al. <b>Interleukin-6 blocking agents for treating COVID-19: a living systematic review.</b> Cochrane Database Syst Rev. 2021;3:CD013881. 33734435.
Medical subject headings
- Interleukin-6
- COVID-19 Drug Treatment